In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy
- Resource Type
- Authors
- Marc Dhenain; Mathieu Santin; Thierry Delzescaux; Caroline Cohen; Michel E. Vandenberghe; Anne-Sophie Hérard; Thomas Debeir; Laurent Pradier; Thomas Rooney
- Source
- Frontiers in Aging Neuroscience
Frontiers in Aging Neuroscience, Frontiers, 2016, 8, ⟨10.3389/fnagi.2016.00055⟩
Frontiers in Aging Neuroscience, 2016, 8, ⟨10.3389/fnagi.2016.00055⟩
Frontiers in Aging Neuroscience, Vol 8 (2016)
- Subject
- Aging
Pathology
medicine.medical_specialty
Amyloid
[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging
Cognitive Neuroscience
Gadolinium
medicine.medical_treatment
[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology
chemistry.chemical_element
lcsh:RC321-571
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
In vivo
β amyloid
mental disorders
Extracellular
medicine
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
Original Research
medicine.diagnostic_test
biology
business.industry
amyloid
Magnetic resonance imaging
Immunotherapy
[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy
Alzheimer's disease
3. Good health
chemistry
MRI imaging
biology.protein
Alzheimer
immunotherapy
Antibody
gadolinium
business
030217 neurology & neurosurgery
Neuroscience
MRI
- Language
- English
- ISSN
- 1663-4365
International audience; Extracellular deposition of β amyloid plaques is an early event associated to Alzheimer's disease. Here, we have used in vivo gadolinium-stained high resolution (29 * 29 * 117 µm 3) magnetic resonance imaging (MRI) to follow-up in a longitudinal way individual amyloid plaques in APP/PS1 mice and evaluate the efficacy of a new immunotherapy (SAR255952) directed against protofibrillar and fibrillary forms of Aβ. APP/PS1 mice were treated for 5 months between the age of 3.5 and 8.5 months. SAR255952 reduced amyloid load in 8.5-months-old animals, but not in 5.5-months animals compared to mice treated with a control antibody (DM4). Histological evaluation confirmed the reduction of amyloid load and revealed a lower density of amyloid plaques in 8.5-months SAR255952-treated animals. The longitudinal follow-up of individual amyloid plaques by MRI revealed that plaques that were visible at 5.5 months were still visible at 8.5 months in both SAR255952 and DM4-treated mice. This suggests that the amyloid load reduction induced by SAR255952 is related to a slowing down in the formation of new plaques rather than to the clearance of already formed plaques.